Advertisement

Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients

      Abstract

      Objective

      To determine if racial and/or socioeconomic factors influence advanced therapy utilization for refractory overactive bladder (OAB) among the commercially insured.

      Methods

      We queried Optum, a national claims database, between 2003 and 2017. Non-neurogenic OAB patients were identified using ICD-9/10 diagnosis codes. Demographic and treatment data were collected, including oral medication therapies (anticholinergic, beta3 agonists), and advanced therapies (OnabotulinumtoxinA [BTX], Sacral Nerve Stimulation [SNS], percutaneous tibial nerve stimulation [PTNS]). Associations between patient sociodemographic factors and advanced therapy utilization were explored.

      Results

      Of 4,229,617 OAB patients, 807,612 (19%) received medical therapies, of which 95% received oral medications only and only 4.7% received advanced therapies. Asians had the lowest use of oral therapy use (14% vs 18%-19% in other races/ethnicities, P <0.05), and advanced therapy use (0.44% vs 0.71%-0.93%, P <0.05). Asians and Hispanics were least likely to utilize SNS therapy and most likely to use PTNS compared to Blacks and Whites. BTX use was similar between races/ethnicities (P <0.05). Female gender (OR 1.65 [CI 1.61,1.69]), younger age (<65) (OR 1.28 [1.25,1.31]), higher annual income ≥$40K (OR 1.09 [1.06,1.12]) and prior use of oral medications (OR 3.30 [3.21,3.38] for 1 medication) were significantly associated with receiving advanced therapies. Non-white race (OR 0.89 [0.87,0.91]), lower education level (less than a bachelor's degree) (OR 0.97 [0.94,0.99]), and Northeast region were associated with a lower likelihood of receiving advanced therapies (P <0.05 for all).

      Conclusion

      Among commercially insured, racial and socioeconomic factors predict utilization of advanced OAB therapies, including race/ethnicity, age, gender, education level, and region.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abrams P
        • Cardozo L
        • Fall M
        • et al.
        The standardization of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.
        Neurology Urodyn. 2002; 21: 167-178
        • Irwin DE
        • Milsom I
        • Hunskaar S
        • et al.
        Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study.
        Eur Urol. 2006; 50: 1306-1315
        • Stewart WF
        • Van Rooyen JB
        • Cundiff GW
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
        • Milsom I
        • Abrams P
        • Cardozo L
        • Roberts RG
        • Thüroff J
        • Wein AJ
        How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study.
        BJU Int. 2001; 87: 760-766
        • Coyne KS
        • Sexton CC
        • Bell JA
        • et al.
        The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL.
        Neurourol Urodyn. 2013; 32: 230-237
        • Sze EH
        • Jones WP
        • Ferguson JL
        • Barker CD
        • Dolezal JM
        Prevalence of urinary incontinence symptoms among black, white, and Hispanic women.
        Obstet Gynecol. 2002; 99: 572-575
        • Tennstedt SL
        • Link CL
        • Steers WD
        • McKinlay JB
        Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey.
        Am J Epidemiol. 2008; 167: 390-399
        • Coyne KS
        • Margolis MK
        • Kopp ZS
        • Kaplan SA
        Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study.
        Urology. 2012; 79: 95-101
        • Thom DH
        • van den Eeden SK
        • Ragins AI
        • et al.
        Differences in prevalence of urinary incontinence by race/ethnicity.
        J Urol. 2006; 175: 259-264
        • Huang AJ
        • Thom DH
        • Kanaya AM
        • et al.
        Urinary incontinence and pelvic floor dysfunction in Asian-American women.
        Am J Obstet Gynecol. 2006; 195: 1331-1337
        • Morrill M
        • Lukacz ES
        • Lawrence JM
        • et al.
        Seeking healthcare for pelvic floor disorders: a population-based study.
        Am J Obstet Gynecol. 2007; 197 (e1-6): 86
        • Willis-Gray MG
        • Sandoval JS
        • Maynor J
        • Bosworth HB
        • Siddiqui NY
        Barriers to urinary incontinence care seeking in White, Black, and Latina women.
        Female Pelvic Med Reconstr Surg. 2015; 21: 83-86
        • Thompson CA
        • Gomez SL
        • Chan A
        • et al.
        Patient and provider characteristics associated with colorectal, breast, and cervical cancer screening among Asian Americans.
        Cancer Epidemiol Biomarkers Prev. 2014; 23: 2208-2217
        • Gormley EA
        • Lightner DJ
        • Burgio KL
        • et al.
        American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
        J Urol. 2012; 188: 2455-2463
        • Lightner DJ
        • Gomelsky A
        • Souter L
        • Vasavada SP
        Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU Guideline Amendment 2019.
        J Urol. 2019; 202: 558-563
        • Laudano MA
        • Seklehner S
        • Sandhu J
        • et al.
        Disparities in the use of sacral neuromodulation among medicare beneficiaries.
        J Urol. 2015; 194: 449-453
        • Syan R
        • Zhang CA
        • Enemchukwu EA
        Trends in the management of overactive bladder in the United States from 2003-2015.
        in: ICS 2018 Annual Meeting. Philadelphia, PA. Abstract # 146. August 28-31, 2018
        • Cameron AP
        • Anger JT
        • Madison R
        • et al.
        National trends in the usage and success of sacral nerve test stimulation.
        J Urol. 2011; 185: 970
        • Anger JT
        • Rodriguez LV
        • Wang Q
        • et al.
        Racial disparities in the surgical management of stress incontinence among female medicare beneficiaries.
        J Urol. 2007; 177: 1846
        • Duralde ER
        • Walter LC
        • Van Den Eeden SK
        • et al.
        Bridging the gap: determinants of undiagnosed or untreated urinary incontinence in women.
        Am J Obstet Gynecol. 2016; 214: 266.e1-266.e9
        • Goldman HB
        • Anger JT
        • Esinduy CB
        • et al.
        Real-world patterns of care for the overactive bladder syndrome in the United States.
        Urology. 2016; 87: 64-69
        • Mckellar K
        • Bellin E
        • Schoenbaum E
        • Abraham N
        Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population.
        Urology. 2019; 126: 70-75
        • Moskowitz D
        • Adelstein SA
        • Lucioni A
        • Lee UJ
        • Kobashi KC
        Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers-are we doing enough?.
        J Urol. 2018; : 779-784